@article {2444, title = {Cytotoxic Potential of Mitragyna speciosa as Anticancer - A Review}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1418-1423}, type = {Review Article}, chapter = {1418}, abstract = {

Background: Herbal treatment has been proposed and researched as an alternative to cancer treatment. One of the reasons contains compounds that have cytotoxic effects. Mitragyna speciosa are known to contain alkaloids and have a cytotoxic effect. Objective: This review aimed to provide information about preclinical studies and investigates the cytotoxicity or anticancer activity of M. speciosa. Methods: Search articles through PubMed, Springer, and Science Direct databases focusing on preclinical trials according to PRISMA guidelines. A database search yielded a total of 206 identifiable studies. Then duplicate removal and feasibility screening were carried out, resulting in 11 studies that were eligible for final analysis. Results: The anticancer potentials reviewed in this study include Neuroblastoma, Leukemia, Colon Cancer, Breast Cancer, Kidney \& Liver Cytotoxicity, Glutathione Transferases Metabolizing Enzymes, Alkaloid Combination of M. speciosa \& Cisplatin, Alkaloid Combination of M. speciosa \& Doxorubicin and Mutagenic-Antimutagenic Activity of M. speciosa. Extracts and dominant alkaloids of M. speciosa have the potential for anticancer neuroblastoma, leukemia, colon, lung and breast cancer. Based on the safety aspect of the mitragynine compound, there is no mutagenic effect on cells. Conclusion: M. speciosa contains the dominant active alkaloid compound, mitragynine. Extracts and alkaloids dominant in M. speciosa have the potential as an anticancer.

}, keywords = {Alkaloids, Cancer, Cytotoxicity, M. speciosa, Mitragynine}, doi = {10.5530/pj.2024.16.228}, author = {Puja Adi Priatna and Retno Widyowati and Sukardiman} } @article {1865, title = {Potential Role of Mitragynine as Lipolysis Stimulator via Adrenergic Signalling: Docking Model Study}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {October 2022}, pages = {527-531}, type = {Original Article}, chapter = {527}, abstract = {

Backgrounds: Mitragynine is the most popular of the more than 50 alkaloids contained in M.Speciosa. In particular, the Mitragynine alkaloid has the potential to increase lipid (fats) metabolism through specific pathways such as adenylyl cyclase signaling via adrenergic receptors. In this case, Asp Amino acid and Ser are the types of residues that can activate adenylyl cyclase to initiate a series of activities in cells. Methods: This study used Mitragynine ligand and adrenergic receptors (α1b, α2a, α2b, α2c dan β1). The receptor candidates were tested using Autodock whose test results were presented in the form of tables and 3-dimensional images using the Biovia Discovery Studio. Results: Hydrogen bonds were formed between Mitragynine and the amino acids Asp and Ser at the β1-adrenergic receptor. The binding amino acids were found in Ser20 and Asp21 with energy bond of -5.26 kcal/mol and IC50: 111.35 ppm. Meanwhile, at the adrenergic receptor α2b there was only Asp residue that formed hydrogen bond with Mitragynine namely Asp218A. The energy bond formed between the two was -5.19 kcal/mol and IC50: 125.04 ppm. Conclusion: Mitragynine has the potential to stimulate lipolysis through the pathways of α2b and β1-adrenergic receptors.

}, keywords = {Adrenergic, Docking, Lipolysis, Mitragynine}, doi = {10.5530/pj.2022.14.130}, author = {Khoirul Rista Abidin and Ronny Lesmana and Mas Rizky Anggun Adipurna Syamsunarno and Kelana Kusuma Dharma} }